secwatch.observer — SEC 8-K summary
======================================

Issuer:     Karyopharm Therapeutics Inc. (KPTI)
CIK:        0001503802
Form:       8-K
Filed at:   2022-12-02T23:59:59+00:00
Accession:  0001193125-22-297530
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Karyopharm amends bylaws for universal proxy rules and meeting procedures
-------------------------------------------------------------------------

- Eliminated requirement to make stockholder list available during meetings.
- Addressed adjournment of stockholder meetings due to technical failure in remote communication.
- Enhanced disclosure and representation requirements for shareholder nominations under universal proxy rules.
- Requires stockholders soliciting proxies to provide evidence of Rule 14a-19 compliance five business days before meeting.
- Non-compliance with Rule 14a-19 will cause Company to disregard nominations and votes for those nominees.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1503802/000119312522297530/0001193125-22-297530-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1503802/000119312522297530/d423713d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-297530

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer